UNSPSC 51372004: Butorphanol

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QV897JC36D, chemically known as morphinan-3,14-diol, 17-(cyclobutylmethyl)- but generally known as butorphanol, which bears US NIH Compound Identifier 2487. Butorphanol most often comes in base and tartrate forms. European Medicines Agency schedules Butorphanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06035MIG.

UNSPSC 51372004 Butorphanol is a Commodity code that in practice covers opioid pharmaceuticals and related pain-management medications procured by state and local health agencies, public health departments, and county community health systems. Recent state and local solicitations under this code show demand for bulk pharmaceutical supplies to support emergency response, addiction treatment, and community health initiatives. The issuing bodies are primarily state health and human services departments, county public health authorities, and cooperative purchasing alliances serving multiple jurisdictions. Procurement vehicles include competitive IFBs for specific unit volumes and RFPs for multi-source pharmaceutical contracting with authorized wholesaler networks, reflecting the regulatory and supply-chain complexity of pharmaceutical procurement at the state and local level.

The most recent activity appears concentrated in Florida and Minnesota, with early-stage market intelligence gathering underway in Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a response deadline of July 26, 2023 and a two-year contract term plus one-year renewal option; the procurement specifies electronic bidding, fixed-fee pricing, drug-free workplace and E-Verify compliance, and potential FEMA funding with associated federal regulatory requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026; vendors must supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), achieve 75 percent evaluation weight on price competitiveness, and maintain $5 million commercial general liability insurance with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering preliminary market intelligence on direct-to-manufacturer prescription program capabilities before formal solicitation, with no award values or binding timelines identified at this exploratory phase.